So, what's the tea on microdosing? It's pretty much what it sounds like — taking smaller doses than the usual prescribed ...

AnaptysBio announces positive results from phase 2b trial of rosnilimab to treat rheumatoid arthritis: San Diego Thursday, June 5, 2025, 18:00 Hrs [IST] AnaptysBio, Inc., a clinic ...

Casma Therapeutics, Inc., a biotechnology company engaging the autophagy and lysosomal systems to develop innovative new medicines, today announced the nomination of its first development candidate, ...

Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, today announced that its third drug candidate, RM-0256, has been ...

Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38.

AnaptysBio (ANAB) hosted a webcast to discuss positive rosnilimab Phase 2b rheumatoid arthritis results and featured two leading rheumatologists, ...

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

CDAI LDA (≤10) was achieved by 45% of 318 rosnilimab patients by Week 12, increasing to 69% (220 responders) across all doses ...

Sanofi and BMS paid big money for rare disease and cancer assets, while Regeneron got in the obesity game; AstraZeneca, Gilead and Amgen shone at ASCO; RFK Jr. and the CDC appeared to disagree over ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the Poster Session: Genitourinary Cancer - Prostate, ...

Favorable safety and tolerability, particularly when compared to standard of care biologics or JAKs Max response rates have not yet been observed; strict continuation criteria at three months in this ...

Researchers are trying to better understand how co-mutations and PD-L1 expression impact response to single-agent KRAS G12C ...